FDA limits first-line bladder cancer labels for Keytruda, Tecentriq

The Food and Drug Administration has announced that it will restrict the use of Merck & Co.'s Keytruda and Roche's Tecentriq in first-line bladder cancer to patients who express high levels of PD-L1.